학술논문

Infusional gemcitabine plus docetaxel/melphalan/carboplatin (GemDMC) +/- bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT).
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; MAY 20 2017, 35 6p. Supplement: 15
Subject
Language
English
ISSN
15277755